A Study to Evaluate Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis in Germany

Last updated: June 2, 2025
Sponsor: Bristol-Myers Squibb
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Scalp Disorders

Warts

Rosacea

Treatment

Deucravacitinib

Clinical Study ID

NCT06104644
IM011-250
  • Ages > 18
  • All Genders

Study Summary

The purpose of this observational study is to describe the effectiveness of deucravacitinib treatment and quality of life in adults with moderate-to-severe plaque psoriasis in routine clinical practice in Germany over a 5-year period

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients with a physician-reported diagnosis of moderate-to-severe plaque psoriasisinitiating deucravacitinib according to approved label in the European Union

  • The decision upon treatment with deucravacitinib must have been made beforeenrollment and independently of this non-interventional observational study

  • Patient is at least 18 years of age at the time of treatment decision

  • Patient provided written informed consent to participate in the study

Exclusion

Exclusion Criteria:

  • Any contraindications according to the approved deucravacitinib Summary of ProductCharacteristics

  • Prior treatment with deucravacitinib

  • Simultaneous participation in an interventional clinical trial formoderate-to-severe psoriasis

Study Design

Total Participants: 550
Treatment Group(s): 1
Primary Treatment: Deucravacitinib
Phase:
Study Start date:
April 13, 2023
Estimated Completion Date:
May 31, 2030

Connect with a study center

  • Dermatologische Spezial- und Schwerpunktpraxis Selters

    Selters, Rhineland-Palatinate
    Germany

    Site Not Available

  • Company for Medical Study & Service Selters

    Selters, 56242
    Germany

    Active - Recruiting

  • Local Institution - 0001

    Selters, 56242
    Germany

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.